Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative o
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-02 8:00 AM EDT | Elite Pharmaceuticals, Inc.
PreveCeutical Adopts Semi-Annual Financial Reporting
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi
Biotechnology, Pharmaceuticals, Health
2026-04-01 4:00 PM EDT | PreveCeutical Medical Inc.
Jam For Cam Raises More Than $1.2 Million for Skin Cancer Research and Awareness with Jam in the Streets
Athens, Georgia--(Newsfile Corp. - April 1, 2026) - Athens-based nonprofit organization Jam For Cam raised more than $1.2 million for skin cancer research and detection with its Jam in the Streets festival Saturday, which attracted more than 25,000 people to Downtown Athens. Jam in the Streets featured 19 performances across seven stages, headlined by Goose. The festival honored the dream of Cameron Fearon, a University of Georgia student who passed away at 19 from metastatic melanoma.
2026-04-01 2:48 PM EDT | Jam For Cam
Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status
Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector. In 2025, Adi
Healthcare and Hospitals, Health
2026-04-01 10:07 AM EDT | Adia Nutrition Inc.
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate us
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-01 9:20 AM EDT | Red Light Holland Corp.
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-01 7:30 AM EDT | Bloom Burton & Co. Inc.
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure. Advanced CRD-38 program, a novel next generation drug intended for use in heart failure an
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-04-01 7:27 AM EDT | Cardiol Therapeutics Inc.
Scryb Reports 2026 AGM Results and Welcomes Veteran Capital Markets and Finance Directors
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce the results of its Annual General Meeting of shareholders (the "AGM") held on March 31, 2026. All resolutions presented at the AGM received overwhelming shareholder support, with more than 99% of votes cast in favour. This strong approval reflects shareholder confidence in the Company's management team, leadership, refreshed strategy, and long-
Biotechnology, Healthcare and Hospitals, Health
2026-04-01 7:06 AM EDT | Scryb Inc.
Dr. Christina Rahm Named One of MSN's "Top 10 Trailblazing Women in 2026"
Franklin, Tennessee--(Newsfile Corp. - March 31, 2026) - Dr. Christina Rahm, a recognized leader in science and innovation, has been selected as one of "MSN's Top 10 Trailblazing Women in 2026," a prestigious honor spotlighting women whose work is reshaping industries and driving meaningful impact across communities. The recognition appears in MSN's feature highlighting women at the forefront of change this year. "I'm truly honored to be featured in MSN's "Top 10 Trailbl
Biotechnology, Food / Beverages, Health
2026-03-31 6:03 PM EDT | DRC Ventures
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc.
Biotechnology, Pharmaceuticals, Health
2026-03-31 4:02 PM EDT | BioHarvest Sciences Inc.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program is being conducted under a contract sig
Biotechnology, Pharmaceuticals, Health
2026-03-31 8:00 AM EDT | BioHarvest Sciences Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to provide a corporate update from Dr. Carolyn Myers, the Company's President and CEO. Dear FendX Shareholders, Over the past several months, FendX has achieved meaningful pro
Technology, Healthcare and Hospitals, Health
2026-03-31 7:00 AM EDT | FendX Technologies Inc.
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial
Technology, Biotechnology, Health
2026-03-31 6:30 AM EDT | Therma Bright Inc.
Functional Brands Announces Fourth Quarter and Full-Year 2025 Financial Results
Lake Oswego, Oregon--(Newsfile Corp. - March 30, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 highlights Revenue of $1.50 million compared to $1.68 million in the prior year period, a decrease of approximately 11.0%. This decrease was primarily due to the shift i
Household / Consumer / Cosmetics, Health
2026-03-30 8:00 AM EDT | Functional Brands Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy com
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-30 7:00 AM EDT | TempraMed Technologies Ltd.
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executi
Biotechnology, Pharmaceuticals, Health
2026-03-30 3:00 AM EDT | PreveCeutical Medical Inc.
The Future of Skin Aging May Be Found in The Kitchen: 2026 American Academy of Dermatology Annual Meeting to Highlight Latest Advancements in Skin, Hair, and Nails
Denver, Colorado--(Newsfile Corp. - March 27, 2026) - As interest grows in how lifestyle factors can influence people's appearance, dermatologists are taking a closer look at how diet may affect the internal and structural changes that contribute to the appearance of aged skin. Emerging research on the role of nutrition in skin aging is one of the timely and impactful topics that will be discussed at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31 in Denver, Co
Healthcare and Hospitals, Health
2026-03-27 9:00 AM EDT | American Academy of Dermatology
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
Glow Lifetech Reduces Over 41 Million Warrants and 5 Million Options, Strengthening Capital Structure; All $0.05 Warrants Now Expired
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce a significant reduction in its outstanding share purchase warrants and stock options during the first quarter of 2026, marking an important milestone in the Company's ongoing efforts to further simplify its capital structure and reduce potential dilution. Significant Reduction in Warrant and Option Overhang
2026-03-27 7:30 AM EDT | Glow Lifetech Corp.